Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Mar 11, 2013 7:07pm
94 Views
Post# 21113335

RE: Swimming with the Sharks - SAS & Hislop

RE: Swimming with the Sharks - SAS & Hislop

Terry:

 

[S] Synergies with this SAS team are better aligned than the previous "team". The following BTV (promotional) link gives an excellent overview of the POTENTIAL combination of BRD&SAS at Hislop.

 

https://www.youtube.com/embed/h50tWDuWers?rel=0

 

Summary of the recommendation of Christos Doulis of Stonecap Secutities as seen on the above link:

 

"Christos Doulis, Stonecap Securities (3/5/13) "St Andrews Goldfields Ltd. provided an exploration update. . .St Andrew’s exploration programs continue to define additional mineralization that will likely extend mine life at its current operations; the high-grade intercepts from Hislop are particularly exciting due to their close proximity to the existing pit. We continue to believe that St Andrew offers investors good leverage to gold in a politically safe, pro-mining jurisdiction; we are maintaining our Outperform rating and $0.80 target price"
---------------------------------------------

 

BWDIK????...NOTE TO FILE: Black Fox (old Stock) mill SAG will have to accomodate the type of ore as described on the SAS Website. Also on the SAS Website & presentations production at Hislop is being scaled back and used as "make up ore" due to grinding/liberation requirements. Thus the Black Fox mill expansion will have to take this into consideration. Notice the scooptram going into the ramp/decline (with the vent ducting going into the mine). This is what I envisage as a POSSIBLE access method from a point located in the Hislop pit into either of the three Grey Fox veins (aka Neighbour to the North) on trend with the Hislop North drilling.

 

Cheers

Stanley

 

Bullboard Posts